1. Phase II evaluation of VP 16-213 (NSC-141540) and cytembena (NSC-104801) in patients with advanced breast cancer;Ahmann;Cancer Treat. Rep.,1976
2. Podophyllotoxin derivate VP 16-213;Arnold;Cancer Chemother. Pharmacol.,1979
3. Randomisierte Phase-II-Studie mit VP16-213 (Etoposide) in der Behandlung von fortgeschrittenem Mammakarzinom;Cavalli;Onkologie,1981
4. A phase II study of oral VP16-213 in patients with hepatocellular carcinoma;Cavalli,1981
5. Therapeutic results using VP 16-213 alone or in combination with 5-fluorouracil in liver cancer (hepatoma);Cavalli;Schweiz. Med. Wochenschr.,1977